Mechanisms of Intranasal Deferoxamine in Neurodegenerative and Neurovascular Disease.
Pharmaceuticals (Basel). 2021 Jan 27;14(2):95. doi: 10.3390/ph14020095.
Pharmaceuticals (Basel). 2021.
PMID: 33513737
Free PMC article.
Review.
Identifying disease-modifying therapies for neurological diseases remains one of the greatest gaps in modern medicine. Herein, we present the rationale for intranasal (IN) delivery of deferoxamine (DFO), a high-affinity iron chelator, as a treatment for neurodegener …
Identifying disease-modifying therapies for neurological diseases remains one of the greatest gaps in modern medicine. Herein, we present th …